Trial Profile
A Single-Arm, Open-Label, Multicenter Clinical Trial With Anlotinib Hydrochloride Capsule for Primary Malignant Bone Tumors With Recurrence and Distant Metastases
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2021
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Bone cancer; Chondrosarcoma; Ewing's sarcoma; Malignant fibrous histiocytoma; Osteosarcoma
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 31 May 2020 Results assessing anlotinib activity in patients with relapsed or metastatic primary malignant bone tumor, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 20 May 2019 Planned End Date changed from 31 Oct 2018 to 31 Dec 2019.
- 20 May 2019 Planned primary completion date changed from 31 Oct 2018 to 31 Dec 2019.